Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.75)
# 2,033
Out of 5,012 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $21.54 | -7.15% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $16.12 | -6.95% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $13.49 | -40.70% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $16.11 | +210.37% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $137.00 | -0.73% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $6.24 | +156.41% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $10.17 | +509.64% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $3.07 | +290.88% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $23.12 | +371.45% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $1.88 | +325.53% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $5.54 | +80.51% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $7.95 | +1,157.86% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $14.23 | -57.84% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $4.13 | +408.47% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $162.32 | -85.83% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $29.87 | +20.52% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $21.54
Upside: -7.15%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $16.12
Upside: -6.95%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $13.49
Upside: -40.70%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $16.11
Upside: +210.37%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $137.00
Upside: -0.73%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $6.24
Upside: +156.41%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $10.17
Upside: +509.64%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $3.07
Upside: +290.88%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $23.12
Upside: +371.45%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.88
Upside: +325.53%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $5.54
Upside: +80.51%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $7.95
Upside: +1,157.86%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $14.23
Upside: -57.84%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $4.13
Upside: +408.47%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $162.32
Upside: -85.83%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $29.87
Upside: +20.52%